Alfredo Carrato

Summary

Country: Spain

Publications

  1. ncbi Oxaliplatin: results in colorectal carcinoma
    Alfredo Carrato
    Medical Oncology Service, Elche University General Hospital, Camino de la Almazara 11, 03202 Elche Alicante, Spain
    Crit Rev Oncol Hematol 44:29-44. 2002
  2. doi Capecitabine plus oxaliplatin for the treatment of colorectal cancer
    Alfredo Carrato
    Medical Oncology Department, Elche University Hospital, Camino Almazara 11, Elche, 03203 Alicante, Spain
    Expert Rev Anticancer Ther 8:161-74. 2008
  3. doi Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer
    A Carrato
    Medical Oncology Department, Ramon y Cajal University Hospital, Ctra Colmenar Viejo Km 9, 1, 28034, Madrid, Spain
    Clin Transl Oncol 15:705-11. 2013
  4. doi Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial
    Alfredo Carrato
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    J Clin Oncol 31:1341-7. 2013
  5. pmc Socioeconomic status and exposure to disinfection by-products in drinking water in Spain
    Gemma Castano-Vinyals
    Centre for Research in Environmental Epidemiology CREAL, Barcelona, Spain
    Environ Health 10:18. 2011
  6. ncbi Anti-VEGF therapy: a new approach to colorectal cancer therapy
    Alfredo Carrato
    Medical Oncology Service, Elche University Hospital, Department of Medicine, Miguel Hernandez University, Camino de la Almazara 11, Elche, 03203 Alicante, Spain
    Expert Rev Anticancer Ther 6:1385-96. 2006
  7. ncbi Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients
    Alfredo Carrato
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    Clin Transl Oncol 11:446-54. 2009
  8. doi Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
    Alfredo Carrato Mena
    Medical Oncology Department, Universitary Hospital Ramon y Cajal, Madrid, Spain
    Anticancer Drugs 21:S3-11. 2010
  9. pmc The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study
    Adela Castillejo
    Molecular Oncology Group, Elche University Hospital, Camino Almazara 11, 03203 Elche, Spain
    BMC Cancer 9:406. 2009
  10. pmc Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study
    André F S Amaral
    Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre, Madrid, Spain
    J Natl Cancer Inst 104:1897-904. 2012

Detail Information

Publications63

  1. ncbi Oxaliplatin: results in colorectal carcinoma
    Alfredo Carrato
    Medical Oncology Service, Elche University General Hospital, Camino de la Almazara 11, 03202 Elche Alicante, Spain
    Crit Rev Oncol Hematol 44:29-44. 2002
    ..Ongoing clinical trials will define its role in the adjuvant setting...
  2. doi Capecitabine plus oxaliplatin for the treatment of colorectal cancer
    Alfredo Carrato
    Medical Oncology Department, Elche University Hospital, Camino Almazara 11, Elche, 03203 Alicante, Spain
    Expert Rev Anticancer Ther 8:161-74. 2008
    ..The combination of capecitabine and oxaliplatin, with or without bevacizumab, a monoclonal antibody blocking VEGF, is also being evaluated in early stage colon cancer...
  3. doi Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer
    A Carrato
    Medical Oncology Department, Ramon y Cajal University Hospital, Ctra Colmenar Viejo Km 9, 1, 28034, Madrid, Spain
    Clin Transl Oncol 15:705-11. 2013
    ..To evaluate the efficacy and safety profile of the combination of panitumumab and irinotecan every 3 weeks in a phase II trial as second-line treatment in patients with advanced wild-type (WT) K-RAS colorectal cancer (CRC)...
  4. doi Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial
    Alfredo Carrato
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    J Clin Oncol 31:1341-7. 2013
    ..This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)...
  5. pmc Socioeconomic status and exposure to disinfection by-products in drinking water in Spain
    Gemma Castano-Vinyals
    Centre for Research in Environmental Epidemiology CREAL, Barcelona, Spain
    Environ Health 10:18. 2011
    ..Disinfection by-products in drinking water are chemical contaminants that have been associated with cancer and other adverse effects. Exposure occurs from consumption of tap water, inhalation and dermal absorption...
  6. ncbi Anti-VEGF therapy: a new approach to colorectal cancer therapy
    Alfredo Carrato
    Medical Oncology Service, Elche University Hospital, Department of Medicine, Miguel Hernandez University, Camino de la Almazara 11, Elche, 03203 Alicante, Spain
    Expert Rev Anticancer Ther 6:1385-96. 2006
    ....
  7. ncbi Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients
    Alfredo Carrato
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    Clin Transl Oncol 11:446-54. 2009
    ..In addition, the use of CSF is considered effective when used to mobilise stem cells before high-dose chemotherapy and when used for chemotherapy schedule optimisation in dose-dense and in dose-intense regimens...
  8. doi Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
    Alfredo Carrato Mena
    Medical Oncology Department, Universitary Hospital Ramon y Cajal, Madrid, Spain
    Anticancer Drugs 21:S3-11. 2010
    ..Ongoing studies will elucidate the overall role of this drug in cancer treatment...
  9. pmc The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study
    Adela Castillejo
    Molecular Oncology Group, Elche University Hospital, Camino Almazara 11, 03203 Elche, Spain
    BMC Cancer 9:406. 2009
    ..Its role in colorectal cancer (CRC) has not been established. The aims of this study were to assess the association of TGFBR1*Int7G24A variant with CRC occurrence, patient age, gender, tumour location and stage...
  10. pmc Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study
    André F S Amaral
    Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre, Madrid, Spain
    J Natl Cancer Inst 104:1897-904. 2012
    ..However, little is known regarding urothelial bladder cancer (UBC). We analyzed the association between plasma 25(OH)D(3) and overall risk of UBC, as well as according to stage and FGFR3 molecular subphenotypes...
  11. ncbi Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri
    Eduardo Diaz-Rubio
    Department of Medical Oncology, Hospital Clinico Universitario San Carlos, Madrid, Spain
    J Clin Oncol 25:4224-30. 2007
    ....
  12. ncbi Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors
    Albert Abad
    Medical Oncology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    Anticancer Drugs 15:469-71. 2004
    ..A phase II study in first-line treatment of patients with metastatic colorectal cancer with this dose regimen is ongoing...
  13. ncbi UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors
    Javier Sastre
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Anticancer Drugs 17:417-21. 2006
    ..Eight out of 13 patients (61.5%) with metastatic colorectal cancer achieved stable disease. UFT plus oxaliplatin is a feasible and safe combination. A phase II trial in first-line advanced colorectal cancer is ongoing...
  14. ncbi Treatment recommendations for metastatic colorectal cancer
    Enrique Aranda
    Medical Oncology Department, Hospital Universitario Reina Sofia, Cordoba, Spain
    Clin Transl Oncol 13:162-78. 2011
    ..This article reviews all the previously mentioned issues involved in the management of metastatic CRC and suggests some general recommendations for its treatment...
  15. doi Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma
    Fernando Rivera
    Medical Oncology Department, H U Marqués de Valdecilla, Santander, Spain
    Cancer Chemother Pharmacol 67:75-82. 2011
    ..We performed a phase II trial to explore the efficacy and toxicity of induction irinotecan-cisplatin (IC) followed by concurrent irinotecan-cisplatin and radiotherapy (IC/RT) in this setting...
  16. doi Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor
    Enrique Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain
    Anticancer Drugs 22:477-9. 2011
    ..To our knowledge, this is the first reported case of treatment with sunitinib in a patient with PNET in response to Choi criteria...
  17. pmc Genetic variation in the TP53 pathway and bladder cancer risk. a comprehensive analysis
    Silvia Pineda
    Spanish National Cancer Research Center CNIO, Madrid, Spain
    PLoS ONE 9:e89952. 2014
    ..We carried out an in depth assessment of associations between common germline variants in the TP53 pathway and bladder cancer risk...
  18. doi Whole genome prediction of bladder cancer risk with the Bayesian LASSO
    Evangelina López de Maturana
    Spanish National Cancer Research Center CNIO, Madrid, Spain
    Genet Epidemiol 38:467-76. 2014
    ..The study confirms the difficulty of predicting complex diseases using genetic data, and suggests the limited translational potential of findings from this type of data into public health interventions. ..
  19. ncbi Recommendations on current approach to gastric cancer
    Fernando Rivera
    Medical Oncology Department, Marques de Valdecilla University Hospital, Santander, Spain
    Clin Transl Oncol 11:518-25. 2009
    ..It would be desirable to incorporate biomarker studies in these trials in order to identify the best treatment for each patient...
  20. doi Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma
    María Angeles Vaz
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain
    Anticancer Drugs 22:817-21. 2011
    ..Otherwise after discontinuing sunitinib, the patient had a relapse on the same location; sunitinib has been resumed and was again found to be effective...
  21. doi Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study
    Noemi Garrigós
    Elche University Hospital, Elche, Alicante, Spain
    Clin Transl Oncol 12:142-7. 2010
    ..Recent studies have identified both the prognostic and predictive utility of determining the number of circulating tumour cells (CTC) in patients with solid cancers...
  22. ncbi Spanish registry and screening program for families at high risk of pancreatic adenocarcinoma
    Carmen Guillen-Ponce
    Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain Spanish National Cancer Research Centre, Madrid, Spain
    J Clin Oncol 30:192. 2012
    ..Familial pancreatic cancer (FPC) is defined as: ≥2 first degree relatives with PC and with no other known syndromes. FPC seems to have autosomal dominant inheritance, but the genetic cause is unknown...
  23. pmc Integration Analysis of Three Omics Data Using Penalized Regression Methods: An Application to Bladder Cancer
    Silvia Pineda
    Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    PLoS Genet 11:e1005689. 2015
    ..Our results highlight the importance of integrating omics data by applying appropriate statistical strategies to discover new insights into the complex genetic mechanisms involved in disease conditions. ..
  24. pmc Genetic and non-genetic predictors of LINE-1 methylation in leukocyte DNA
    Salman M Tajuddin
    Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre, CNIO, Madrid, Spain
    Environ Health Perspect 121:650-6. 2013
    ..Altered DNA methylation has been associated with various diseases...
  25. ncbi Adjuvant therapy of resected gastric cancer is necessary
    Alfredo Carrato
    Medical Oncology Service, Elche University Hospital, 03202 Elche, Alicante, Spain
    Semin Oncol 32:S105-8. 2005
    ..New target-oriented agents, as well as tailored therapy based on the molecular profile of both the tumor and the patient, might also contribute to improved results...
  26. pmc Pancreatic cancer risk and levels of trace elements
    André F S Amaral
    Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre CNIO, C Melchor Fernandez Almagro 3, Madrid, Spain
    Gut 61:1583-8. 2012
    ..Among other carcinogens, tobacco contains cadmium, a metal previously associated with an increased risk of EPC. This study evaluated the association between concentrations of trace elements in toenails and EPC risk...
  27. pmc Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis
    Maciej J Czachorowski
    Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    PLoS ONE 7:e45025. 2012
    ..The meta-analysis confirmed these results. We did not find evidence that COX2 expression is an independent prognostic marker of recurrence, progression or survival in patients with UCB...
  28. doi TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis
    Adela Castillejo
    Grupo de Oncología Molecular, Hospital General Universitario de Elche, Elche, Spain
    Int J Cancer 124:608-13. 2009
    ..003). In conclusion, the genetic variants analyzed were not associated with an increased risk of bladder cancer. The association of TGFBR1-rs868 with outcome should be validated in independent patient series...
  29. ncbi Adjuvant chemotherapy for stages II, III and IV of colon cancer
    Cristina Gravalos
    Medical Oncology Service, University Hospital 12 de Octubre, Madrid, Spain
    Clin Transl Oncol 11:526-33. 2009
    ..This article reviews the state of the art and the future perspectives of adjuvant therapy in colon cancer. Prognostic and predictive factors are also commented on...
  30. ncbi Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)
    Vega Iranzo
    Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain
    Clin Transl Oncol 13:411-8. 2011
    ..We conducted a multicentre, open-label, nonrandomised phase II trial to determine the efficacy and tolerability of sequential monotherapy with gemcitabine followed by paclitaxel in chemotherapy-naïve patients with advanced NSCLC...
  31. pmc Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk
    Evangelina López de Maturana
    Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center CNIO, Madrid, Spain
    PLoS ONE 8:e83745. 2013
    ..Here we report, for the first time, a set of SNP in inflammatory genes jointly associated with bladder cancer risk. These results highlight the importance of the complex structure of genetic susceptibility associated with cancer risk. ..
  32. pmc Genetic susceptibility to distinct bladder cancer subphenotypes
    Lin T Guey
    Spanish National Cancer Research Centre, Madrid, Spain
    Eur Urol 57:283-92. 2010
    ..It is conceivable that specific patterns of genetic susceptibility are associated with particular subphenotypes...
  33. doi Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)
    Enrique Grande
    Medical Oncology Service, Ramon y Cajal University Hospital, Madrid, Spain
    Clin Transl Oncol 12:481-92. 2010
    ..In fact, mTOR inhibitors have shown activity in uncontrolled trials, and large, randomised trial results will be available shortly. In this article, we summarise the most recent available data on medical therapy for GEPNETs...
  34. doi Biallelic MYH germline mutations as cause of Muir-Torre syndrome
    Carmen Guillen-Ponce
    Medical Oncology Department, Ramon y Cajal University Hospital, Carretera de Colmenar, Km 9, 100, 28034, Madrid, Spain
    Fam Cancer 9:151-4. 2010
    ..Furthermore, this report contributes to characterize the clinical phenotype caused by biallelic mutations in MYH gene, which may share with other hereditary colon cancer syndromes...
  35. ncbi Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique
    Carlos Camps
    From Consorci Hospital General Universitari València, València Hospital del Mar, Barcelona Hospital Universitario Miguel Servet, Zaragoza Maimónides Institute of Biomedical Research, Hospital Reina Sofia, University of Cordoba, Córdoba Hospital Universitario Ramón y Cajal, Madrid Hospital Universitario de Guadalajara, Guadalajara Hospital 12 de Octubre, Madrid Hospital Salamanca, Salamanca Instituto Valenciano de Oncología, Valencia Hospital Universitario de Cruces, Barakaldo Hospital General Universitario Gregorio Marañón, Madrid Hospital Puerto Real, Cádiz Hospital Clínico Universitario, Valencia Universidad de Cádiz, Cádiz Sociedad Española de Calidad Asistencial, Madrid Hospital Universitario Clínica San Carlos, Madrid, Spain
    J Natl Compr Canc Netw 14:553-8. 2016
    ..The goal of this research was to develop a set of evidence-based quality indicators (QIs) for organization, palliative care, and colorectal, breast, and lung cancers for introducing a system of benchmarking in Spain...
  36. ncbi Genetic differences based on miRNAs of colorectal adenocarcinoma according to age and the presence or absence of MMR defect
    Carmen Guillen-Ponce
    Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain Elche University Hospital, Elche, Spain Directorate General of Public Health of Comunidad Valenciana, Valencia, Spain
    J Clin Oncol 30:495. 2012
    ..We aim to study the expression of miRNAs in CRC patients with Lynch syndrome and in patients with CRC without microsatellite instability (MSI-S) who have developed cancer at different ages...
  37. doi Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy
    Patricia Llovet
    Laboratory of Molecular Oncology, Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Mol Diagn Ther 19:397-408. 2015
    ..However, most patients with KRAS wild-type tumors still do not respond. Other molecules downstream of the EGFR may also play a role in resistance to EGFR therapies...
  38. doi Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level
    Enrique Barrajón-Catalán
    Molecular and Cellular Biology Institute, Miguel Hernandez University, Alicante, Spain
    Cancer Lett 290:192-203. 2010
    ..Trastuzumab resistant breast cancer cells (JIMT-1), can also be targeted using this approach...
  39. doi New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies
    Enrique Grande
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    Expert Rev Anticancer Ther 12:457-67. 2012
    ..In this article we review the rationale for the use of novel ubiquitin-proteasome system inhibitors in gastrointestinal malignancies...
  40. pmc Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer
    Julie Earl
    Medical Oncology Department, Ramon y Cajal University Hospital, Carretera de Colmenar Viejo, Km 9, 100, 28034, Madrid, Spain
    BMC Cancer 15:797. 2015
    ..However, this is hindered due to lack reliable diagnostic and predictive markers which mean that the majority of patients succumb to their condition within a few months...
  41. doi Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study
    Alfredo Carrato
    Hospital Universitario Ramon y Cajal, Madrid, Spain
    Expert Rev Pharmacoecon Outcomes Res 15:579-89. 2015
    ....
  42. pmc The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies
    Julie Earl
    Epithelial Carcinogenesis Group, F BBVA Cancer Cell Biology programme, CNIO Spanish National Cancer Research Centre, Madrid, Spain
    BMC Genomics 16:403. 2015
    ....
  43. pmc Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy
    Cristina Balbás-Martínez
    Epithelial Carcinogenesis Group, Molecular Pathology Programme, CNIO Spanish National Cancer Research Centre, Madrid, Spain
    Nat Genet 45:1464-9. 2013
    ..STAG2 reintroduction in non-expressing cells led to reduced colony formation. Our findings indicate that STAG2 is a new UBC tumor suppressor acting through mechanisms that are different from its role in preventing aneuploidy. ..
  44. doi Follow-up recommendations and risk-reduction initiatives for Lynch syndrome
    Carmen Guillen-Ponce
    Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain
    Expert Rev Anticancer Ther 12:1359-67. 2012
    ..Furthermore, the clinical and biological characteristics of this disease and their potential impact on prevention in individuals at risk are analyzed...
  45. pmc The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study
    Adela Castillejo
    Molecular Oncology Group, Elche University Hospital, Camino Almazara 11, Elche, Spain
    BMC Cancer 9:193. 2009
    ..The aim of this study was to assess the association between TGFBR1*6A and colorectal cancer, age, sex, tumour location and tumour stage in a Spanish population...
  46. doi Occupational exposures and risk of oesophageal cancer by histological type: a case-control study in eastern Spain
    M Santibanez
    Occupational Health Unit, Public Health Center, Elche, Alicante, Spain
    Occup Environ Med 65:774-81. 2008
    ..To explore the relationship between occupations and specific occupational exposures and oesophageal cancer (OC) by histological type...
  47. doi Reduced risk of pancreatic cancer associated with asthma and nasal allergies
    Paulina Gomez-Rubio
    Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center CNIO, Madrid, Spain
    Gut 66:314-322. 2017
    ..This study assessed and characterised the association between PDAC and asthma and corroborated existing reports regarding the association between allergies and PDAC risk...
  48. doi Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers
    Hans Vasen
    Hans Vasen, Isaura Ibrahim, Kristin Robbers, Anneke M van Mil, Thomas Potjer, Bert A Bonsing, Wilma Bergman, Martin Wasser, and Hans Morreau, Leiden University Medical Center, Leiden Wouter H de Vos tot Nederveen Cappel, Isala Clinics, Zwolle, the Netherlands Carmen Guillen Ponce, Alfredo Carrato, Julie Earl, Evelina Mocci, Enrique Vazquez Sequeiros, Alfonso Sanjuanbenito, Maria Muñoz Beltran, and José Montans, Ramon y Cajal University Hospital, Ramón y Cajal Health Research Institute, Madrid, Spain Emily P Slater, Elvira Matthäi, Volker Fendrich, and Detlef K Bartsch, University Hospital Marburg Christoph Schicker, Martin Steinkamp, and Jens Figiel, Philipps University Marburg, Marburg Günter Klöppel, Leeds
    J Clin Oncol 34:2010-9. 2016
    ..Surveillance of high-risk groups, may facilitate detection of PDAC at an early stage. The aim of this study was to assess whether surveillance aids detection of early-stage PDAC or precursor lesions (PRLs) and improves the prognosis...
  49. pmc Prognostic value of stem cell quantification in stage II colon cancer
    María Angeles Vaz
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    PLoS ONE 9:e88480. 2014
    ..The aim of this study is to evaluate the prognostic value of CSCs in a highly homogeneous population of stage II colon cancer...
  50. doi Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients
    Lucy A Parker
    Department of Public Health, Miguel Hernandez University, Alicante, Spain
    Eur J Epidemiol 26:229-36. 2011
    ..However, it seems premature to rule out the utility of K-ras analysis in conjunction with other genetic and 'omics' technologies...
  51. ncbi Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis
    M José Molina-Garrido
    Department of Oncology, General University Hospital in Elche, Elche, Alicante, Spain
    Clin Transl Oncol 10:241-5. 2008
    ..This case report shows the number of tests that were made in order to discover the origin of osteolytic and osteoblastic lesions and it is notable that there is not an occult neoplasia on every occasion...
  52. ncbi Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study
    Albert Abad
    Institut Catala Oncologia, Servicio de Oncologia Medica, Hospital Germans Trias i Pujol, Barcelona Cta Canyet s n, Barcelona, Spain
    Acta Oncol 47:286-92. 2008
    ....
  53. ncbi Capecitabine as adjuvant treatment for stage III colon cancer
    Chris Twelves
    University of Leeds and Bradford NHS Hospitals Trust, Leeds, United Kingdom
    N Engl J Med 352:2696-704. 2005
    ..The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting...
  54. ncbi Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer
    Albert Abad
    Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Ctra Canyet, s n 08916 Badalona, Barcelona, Spain
    Clin Colorectal Cancer 4:384-9. 2005
    ..9% and 16.7%). Biweekly oxaliplatin in combination with nonmodulated high-dose 5-FU is an active, well-tolerated treatment that offers a lower cost than a modulated schedule for patients with advanced, metastatic CRC...
  55. ncbi Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study
    Javier Sastre
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, c Profesor Martín Lagos, S N, 28040 Madrid, Spain
    J Clin Oncol 23:3545-51. 2005
    ..This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients...
  56. ncbi Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer
    Angel Artal-Cortes
    Hospital Universitario Miguel Servet, Zaragosa, Madrid Spain
    Clin Lung Cancer 6:175-83. 2004
    ..Epirubicin/cisplatin showed a similar activity with a slightly lower toxicity profile than the reference regimen of etoposide/cisplatin. The epirubicin/cisplatin regimen may be recommended in the treatment of SCLC...
  57. pmc Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study
    Lee E Moore
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Rockville, MD, USA
    Lancet Oncol 9:359-66. 2008
    ..DNA hypomethylation has been suggested to cause genomic instability and increase cancer risk. We aimed to test the hypothesis that DNA hypomethylation is associated with increased risk of bladder cancer...
  58. ncbi The p53 pathway and outcome among patients with T1G3 bladder tumors
    Elena Lopez-Knowles
    Institut Municipal d Investigacio Medica, Universitat Pompeu Fabra, and Hospital del Mar, Barcelona, Spain
    Clin Cancer Res 12:6029-36. 2006
    ..The aim was to analyze Tp53 and HDM2 in T1G3 bladder tumors and to determine the prognostic value of their alterations...
  59. ncbi Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group
    Bernard Nordlinger
    Hopital Ambroise Pare, CHU Paris Ouest, 92100 Boulogne Cedex, France
    Eur J Cancer 43:2037-45. 2007
    ....
  60. ncbi Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study
    Lars Dyrskjøt
    Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark
    Clin Cancer Res 13:3545-51. 2007
    ..Here, we validated four previously reported gene expression signatures for molecular diagnosis of disease stage and carcinoma in situ (CIS) and for predicting disease recurrence and progression...
  61. pmc Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk
    Montserrat Garcia-Closas
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland, United States of America
    PLoS Genet 3:e29. 2007
    ..In conclusion, this large-scale evaluation of candidate cancer genes has identified common genetic variants in the regulatory regions of VEGF that could be associated with bladder cancer risk...
  62. ncbi Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage
    Miquel Porta
    Unidad de Epidemiología Clinica y Molecular del Cáncer, Instituto Municipal de Investigacion Medica, Universidad Autonoma de Barcelona, Carrer del Dr Aiguader 80, 08005 Barcelona, Spain
    Clin Transl Oncol 7:189-97. 2005
    ..We recorded the signs and symptoms of patients presenting with exocrine pancreatic cancer and evaluated their association with clinical characteristics such as tumour site and disease stage...
  63. ncbi Genetic variation in the nucleotide excision repair pathway and bladder cancer risk
    Montserrat Garcia-Closas
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Room 7076, 6120 Executive Boulevard, MSC 7234, Rockville, MD 20852 7234, USA
    Cancer Epidemiol Biomarkers Prev 15:536-42. 2006
    ..A detailed characterization of genetic variation in key NER genes is warranted and might ultimately help identify multiple susceptibility variants that could be responsible for substantial joint increases in risk...